Clinical trials: Diabetes Mellitus, Type 2/Prevention & Control
- Condition Diabetes Mellitus, Type 2/Prevention & Control
- Funder type Industry (pharma, biotech, devices)
Prediabetic State
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e.
- Trial name
- RAPSODI (NCT00325650)
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 2,420 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Metabolic Syndrome, Obesity & Overweight
Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women
This study evaluated the SWW Method®, a 12-week dietary and lifestyle intervention based on the carbohydrate-insulin model, in a healthy cohort of women aged 35-75.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring, Type 2 Diabetes Prevention
- Trial name
- NCT07463417
- Testing
- SWW Method® Dietary and Lifestyle Intervention
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Sarah Wragge Wellness
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer